In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alimera Sciences Inc.

www.alimerasciences.com

Latest From Alimera Sciences Inc.

Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy

The latest drug development news and highlights from our FDA Performance Tracker.

Drug Review Approvals

Early Yutiq Approval Gives EyePoint Two Ophthalmic Drugs To Launch In 2019

Yutiq, for posterior uveitis, will compete with two existing steroid products and should launch during the first quarter of 2019. EyePoint’s Dexycu, although approved in February, is still in scale-up and probably will launch a bit later.

Approvals Ophthalmic

Pipeline Watch: Phase III Progress With Keytruda, Bempedoic Acid And Ubrogepant

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Approvals Pipeline Watch

Finance Watch: Hua Medicine Raises $117.4m While Evaluating A Hong Kong IPO

Hua, already considering an IPO in Hong Kong for up to $400m, closed concurrent VC rounds that will fund its late-stage diabetes program in China, but it may still need to go public to enter other markets. Also, Heron raised cash for its next commercial product, among other public company financings.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Implantable Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alimera Sciences Inc.
  • Senior Management
  • Dan Myers, CEO
    Richard S Eiswirth, Pres. & CFO
    Ken Green, PhD, CSO
    David R Holland, SVP, Sales & Mktg.
  • Contact Info
  • Alimera Sciences Inc.
    Phone: (678) 990-5740
    6120 Windward Pkwy., Ste. 290
    Alpharetta, GA 30005
    USA
UsernamePublicRestriction

Register